

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**PRIMARY ENDPOINTS ACHIEVED**  
**IN THE PHASE II CLINICAL TRIAL OF OT-202**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that, the phase II clinical trial of OT-202 (tyrosine kinase inhibitor), a first-in-class new drug self-developed by the Company for the treatment of dry eye, has successfully completed the unblinding with all related data collected, which marks OT-202 has achieved the primary clinical endpoint of phase II clinical trial, i.e., the group that received the treatment with the drug exhibited greater improvement in corneal staining scores from baseline compared to the placebo group by day 56. The drug has also demonstrated positive results in safety and efficacy. The Company expects to launch phase III clinical trial of OT-202 in the near future.

OT-202 (tyrosine kinase inhibitor) is a first-in-class new drug self-developed by the Company for the treatment of moderate to severe dry eye. The mechanism of action of OT-202 is that the dualtargeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor-2 achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial successfully completed in February 2023. The phase II clinical trial of OT-202, which was launched in February 2023 and designed to be a randomized, double-masked, placebo-controlled clinical trial on the safety and efficacy of the drug, has completed the enrollment of a total of 213 patients for the phase II clinical trial in China in November 2023.

**Cautionary Statement:** The Company cannot guarantee that it will ultimately commercialize OT-202 (tyrosine kinase inhibitor) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, March 14, 2024

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*